Short-Term Debt to Equity Ratio: Coya Therapeutics (COYA)
Coya Therapeutics, Inc. (COYA) maintains a high reputation for developing T-regulatory cell-based therapies to combat ALS. The business model relies on outsourcing production to third-party contractors under strict supervision. This chart shows the market price reaching 0.00, which correlates with successes in treating Alzheimer's disease, patent protection, and potential interest from global pharmaceutical behemoths.
Metric breakdowns and analytics for Coya (COYA)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Capital Coya Therapeutics, Inc.|COYA - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Coya Therapeutics, Inc.|COYA - Company Cumulative Debt|Debt to Book Value Coya Therapeutics Inc|COYA - Long-Term Debt|Company Short-Term Debts Coya Therapeutics|Quick Liquidity Indicator coyatherapeutics.com
- company profitability and valuation multiples indicators:
Analysis of all company metrics:Coya Therapeutics COYA
Utilizing external CDMO partners to scale biologics in the US allows Coya Therapeutics, Inc. (COYA) to optimize capital expenditures by minimizing the need for long-term loans. This indicator measures the proportion of short-term liabilities relative to equity, reflecting current liquidity and the balance sheet's reliance on quick loans, which is clearly evidenced by the trend in the short-term debt-to-equity ratio.
Competitors of Coya Therapeutics, Inc. (COYA)
Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Supernus Corp (SUPN)|CPRX (Catalyst Pharmaceuticals) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio denalitherapeutics.com (DNLI)|Short-Term Debt to Equity Harmony Biosciences Holdings, Inc. (HRMY)|BHVN - Current Liabilities to Capital|Amylyx - Short-Term Debt to Equity Ratio|Trevi Corp (TRVI) - Current Liabilities to Capital|Praxis Precision Medicines - Short-Term Debt to Capital|AVXL - Short-Term Debt to Capital|CBLL (CeriBell) - Short-Term Debt to Equity Ratio|Prothena Biosciences - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio ALEC|ANNX (Annexon Biosciences Inc.) - Short-Term Loans to Capital Ratio|Short-Term Debt to Capital OMER|NGNE (neurogene.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital ACIU (AC Immune SA)|Voyager Therapeutics Inc (VYGR) - Current Liabilities to Capital|NMRA - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital SCLX (Scilex Holding Company, Inc.)|TVGN: Short-Term Debt to Capital|Alpha Cognition Inc. (ACOG) - Short-Term Debt to Capital|Short-Term Debt to Equity Cognition Therapeutics, Inc.|Inhibikase Therapeutics Inc - Current Liabilities to Equity|Short-Term Debt to Capital SAVA|ASRT - Current Liabilities to Capital|Vistagen - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital Ovid Therapeutics Inc OVID|ABOS: Short-Term Debt to Equity Ratio|CervoMed, Inc. - Short-Term Loans to Capital Ratio|ATHE: Short-Term Debt to Capital|CLNN - Short-Term Debt to Capital Coefficient|PEPG (PepGen Inc) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio jupiterneurosciences.com (JUNS)|Short-Term Debt to Equity Relmada Therapeutics, Inc. (RLMD)|Short-Term Debt to Capital Coefficient Annovis Bio Inc|Grace Therapeutics - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital AIFF|ANEW Medical, Inc. - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient NeuroSense Therapeutics NRSN|Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Short-Term Debt to Equity|Short-Term Debt to Capital Ratio MTVA|NRXS (NeurAxis, Inc) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio Helius Medical Technologies Inc. (HSDT)|Short-Term Debt to Equity Ratio PASG (Passage Bio, Inc.)|Short-Term Debt to Capital Coefficient bionomics.com.au|Short-Term Debt to Capital NERV (Minerva Neurosciences, Inc.)|ATHA - Short-Term Debt to Equity Ratio|ADXN - Short-Term Debt to Equity|Current Liabilities to Capital Alzamend Neuro, Inc.|CYCN (cyclerion.com) - Short-Term Debt to Equity Ratio|Current Liabilities to Capital Protagenic Therapeutics, Inc. (PTIX)|KTTA (Pasithea Therapeutics Corp) - Short-Term Debt to Capital|Short-Term Debt to Capital Cortigent Medical|Short-Term Debt to Equity Avenue Therapeutics, Inc (ATXI)|BrainStorm Cell Therapeutics Inc. - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital CARA (Cara Therapeutics, Inc.)|chromocell.com (CHRO) - Current Liabilities to Capital|ELYM: Short-Term Debt to Equity Ratio|ITCI - Short-Term Debt to Capital|Longboard Pharma (LBPH) - Short-Term Debt to Equity|Marinus Pharma - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity NKGen Biotech, Inc.|Current Liabilities to Capital neurobopharma.com NRBO|Short-Term Debt to Capital SAGE|Short-Term Debt to Equity Ratio Synaptogenix Inc. SNPX|Short-Term Debt to Equity Trevena, Inc TRVN|Vigil Neuroscience Inc. (VIGL) - Current Liabilities to Capital|WENA: Short-Term Debt to Equity Ratio|Current Liabilities to Capital cerevel.com